RxDoctor Payments Data

Nicholas Iannazzo, DO

Pulmonary Disease · Indianapolis, INNPI 1043669633

Payments from drug & device makers

$291in general payments, 2019–2025

Across 10 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$121
  • Regeneron Healthcare Solutions, Inc.$49
  • AstraZeneca$31
  • Viatris Specialty LLC$22
  • Novartis$19
  • Sanofi$18
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$291 in reported general payments places this provider in the 20th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$44,721
Medicare patients
141
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate26$335,297
Spiriva HandihalerTiotropium Bromide14$10,252
SymbicortBudesonide/Formoterol Fumarate27$6,833
Spiriva RespimatTiotropium Bromide11$5,871
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,794
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$1,727
Albuterol Sulfate HfaAlbuterol Sulfate35$775
Mycophenolate Mofetil11$725
Prednisone32$258
Fluticasone Propionate12$148
Montelukast Sodium39$139
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$127
Omeprazole11$125
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$31$6,83327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →